GW Link

Find Nonprofit and Small Business Grants

Advance Search

Only Available for Paid Subscribers
Clear Filters
Search Filters

Clinical Investigator Career Development Award (CDA)

Grants to USA and Canada Physician Investigators to Support
Efforts Related to Lymphoma Treatment and Research

Agency Type:

Foundation / Corporation

Funding Source:

Add to My Calendar 

Lymphoma Research Foundation (LRF)

Deadline Date:

09/05/19 5:00 PM EST

Description:

Request a Grant Writer

Grants to USA and Canada early career investigators to support efforts related to lymphoma treatment and research. Funding is intended to support advanced-fellow and junior-faculty physician researchers who are involved in developing new lymphoma therapies and diagnostic tools. The goal of the program is to prepare physician investigators to design and administer clinical research studies in lymphoma and assume primary responsibilities for clinical research, protocol writing, Institutional Review Board (IRB) submission, and publication.

A Career Development Plan is required as part of the Grant Application. The proposed research plan should develop the necessary knowledge and clinical research skills relevant to the investigator’s career goals. The Grant is designed to provide physician investigators with support to spend 35-50 percent of their time implementing clinical research studies in lymphoma.

All projects must be focused on hypothesis-driven clinical research in lymphoma. The Foundation considers “lymphoma” to encompass all recognized lymphoma subtypes as well as chronic lymphocytic leukemia (CLL). The project should be developed by the Applicant and should include at least the framework of a research protocol. Review of Applications will be based on, but not be limited to, the following factors. Each factor will be judged in reference to its relevance to clinical research in lymphoma:
- Applicant qualifications, relevant clinical research experience, and commitment to pursuing a career in lymphoma clinical research.
- Mentor(s)’s qualifications and record of success in training independent Clinical Investigators.
- Career Development Plan, which clearly leads to research independence.
- Innovation of proposed research strategy and objectives.
- Relevance and research impact to the future of lymphoma treatment.
- Research Implementation Plan.
- Availability of resources, such as facilities and patient study group, to support the project.

GrantWatch ID#:

GrantWatch ID#: 186434

Estimated Size of Grant:

The LRF Clinical Investigator Career Development Award provides a total of $225,000 to grantees over three years. The Grant provides salary support in the amount of $70,000 per year. Incidental funds of $5,000 per year which may be budgeted for research supplies or professional development expenses such as tuition, registration fees, and travel for courses and meetings that are integral to the Career Development Plan.

Term of Contract:

Funding will commence at the earliest on March 1, 2020. The contract term is three years.

Additional Eligibility Criteria:

Applicant eligibility:
1. Applicants must be licensed physicians at a clinical research institution in the United States or Canada for the duration of the LRF Clinical Investigator Career Development Grant, and intending to pursue a career in lymphoma clinical research.
2. Applicants for this award should be clinical physicians in one of the ACGME accredited specialties (e.g., hematology/oncology, pediatrics, pathology, dermatology, radiation oncology).
3. The applicant must be an advanced fellow or junior faculty member with at least 2 years (24 months) of fellowship or postdoctoral training and no greater than 5 years of experience beyond completion of his/her fellowship or post doctoral training (the five year limit may be non-sequential) at the start of the award period (March 1, 2020). Persons with non-traditional career tracks are encouraged to apply. They should have participated in developing new therapeutics and/or diagnostic tools for lymphoma.
4. Applicants must demonstrate that they already possess a broad knowledge of lymphoma biology and treatment and their desire to apply this knowledge to developing and evaluating new treatments.
5. The Clinical Investigator must spend 35 to 50 percent of his/her time in research. This time should be free of major patient care, teaching or administrative responsibilities.
6. The Clinical Investigator will have primary responsibility for the design, protocol writing, IRB submission, conduct, analysis and publication of one or more clinical trials during the award period.
7. Please note: The LRF CDA recipient will not be permitted to hold any other career development award during the award period of the LRF grant. Examples of grants that fall in this category include NIH K-series awards, American Cancer Society Clinician Scientist Development Grant, ASH Scholar Awards, Leukemia and Lymphoma Society Career Development Program Grants (any level of Fellow or Scholar grants) and/or any grant termed a “career development award” or which supports primarily principal investigator (PI) salary.

A Primary Mentor at the Applicant’s home institution must be identified in the application and this individual’s role in the training and research activities of the applicant must be described, including a plan for periodic evaluation of the applicant’s progress. The Primary Mentor will be responsible for signing the application cover sheet and, if the award is granted, completing the designated section of annual progress reports. Primary Mentors may only support one CDA applicant per cycle.

Beginning with the 2019 cycle, grantees may not simultaneously hold career development awards from other foundations even if there are no overlapping expenses with the LRF grant. Supply and material costs for the clinical research project should be supported by institutional funds or another grant which is not a career development award; funds from an NIH Institutional Training grant (T32/K12 or equivalent) are considered part of the “institutional funds” category and are allowable.

The percent of research time for the PI on all active grants should not add up to more than 100%. LRF must be informed as to the sources and the amounts of all extramural/non-institutional funding received by the CDA recipient during the term of the LRF Grant, and reserves the right to determine that the LRF Grant may not be held concurrent with other funding.

Pre-Application Information:

The application deadline is 5:00 PM EST, September 5, 2019. Applications should be submitted through proposedCENTRAL.

To avoid being rushed at deadline time, applicants are encouraged to register and complete a professional profile at proposalCENTRAL now. Applicants should make sure their grants and contracts office has registered their institution and signing officials with proposalCENTRAL, and that they acquaint themselves with any internal approval processes required by their institution’s grant office.

Key Dates:
- Application Release Date: May 31, 2019
- Application Deadline: September 5, 2019 at 5:00 PM EST
- Peer Review Process: September – November 2019
- Applicant Notification Date: December 2019
- Earliest Project Start Date: March 1, 2020

Contact Information:

Before starting your grant application, please review the funding source's website listed below for updates/changes/addendums/conferences/LOIs.

Apply online: https://proposalcentral.com/ProposalGI.asp?SectionID=722&ProposalID=-1

For technical support:
Phone: 800-875-2562(Toll free) or 703-964-5840
E-mail: pcsupport@altum.com

Foundation contact:
Whitney Steen, Senior Manager, Research Grants and Communications
Phone: 212-349-2910
researchgrants@lymphoma.org

URL for Full Text (RFP):

Geographic Focus:

USA: Alabama;   Alaska;   Arizona;   Arkansas;   California;   Colorado;   Connecticut;   Delaware;   Florida;   Georgia;   Hawaii;   Idaho;   Illinois;   Indiana;   Iowa;   Kansas;   Kentucky;   Louisiana;   Maine;   Maryland;   Massachusetts;   Michigan;   Minnesota;   Mississippi;   Missouri;   Montana;   Nebraska;   Nevada;   New Hampshire;   New Jersey;   New Mexico;   New York City;   New York;   North Carolina;   North Dakota;   Ohio;   Oklahoma;   Oregon;   Pennsylvania;   Rhode Island;   South Carolina;   South Dakota;   Tennessee;   Texas;   Utah;   Vermont;   Virginia;   Washington, DC;   Washington;   West Virginia;   Wisconsin;   Wyoming

Canada: Alberta   British Columbia   Manitoba   New Brunswick   Newfoundland and Labrador   Northwest Territories   Nova Scotia   Nunavut   Ontario   Prince Edward Island   Quebec   Saskatchewan   Yukon